S1 Biopharma Inc.
Drugs for sexual dysfunction
This article was originally published in Start Up
Executive Summary
Pharmacological intervention for men with sexual dysfunction has become accepted medical practice, but treatment for women has lagged behind. S1 Biopharma Inc. hopes to change that: it was founded with the purpose of identifying and developing solutions for common, untreated sexual dysfunctions that affect women.
You may also be interested in...
Women’s Health: Moving Beyond Gynecology To Sexuality
Big Pharma’s exodus from women’s health has created opportunities for biotech start-ups, which hope to tap into potentially huge markets. Profiles of Evestra Pharmaceuticals, S1 Biopharma, and Sprout Pharmaceuticals.
Homology Medicines Inc.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.